Dapagliflozin for Acute Myocardial Infarction Patients

Inclusion Criteria: * Men and women aged ≥ 18 years (women of childbearing age must have a negative pregnancy test); * In routine use of dual antiplatelet therapy with ASA plus an ADP receptor antagonist, according to institutional routines; * Acute myocardial infarction, with or without ST-segment elevation (STEMI/NSTEMI) defined according to the 4th Universal Definition of Acute Myocardial Infarction, with up to 7 days of evolution from the onset of symptoms; * Signature of the Free and Informed Consent Term. Exclusion criteria: * Current or recent (within 24 months) treatment with pioglitazone and/or use of pioglitazone for a total of 2 years or more during a lifetime at any time; * Current or recent (within 12 months) treatment with rosiglitazone; * Chronic use (\>15 consecutive days) of any SGLT2 inhibitor at the time of hospitalization; * Chronic use (\>30 consecutive days) with an oral steroid at a dose equivalent to prednisolone ≥10 mg (eg, betamethasone ≥1.2 mg, dexamethasone ≥1.5 mg, hydrocortisone ≥40 mg) per day; * Systolic BP \> 180 or diastolic BP \> 100 mmHg at randomization; * Diagnosis of Type 1 diabetes mellitus, MODY (maturity onset diabetes of the Young) or diabetes mellitus secondary to diverse endocrinopathy, pancreatic resection, medication, pancreas neoplasia or chronic pancreatitis; * History of bladder cancer or history of radiation therapy to the lower abdomen or pelvis at any time; * History of any other malignancy within 5 years (with the exception of skin cancers successfully treated non-melanoma); * Chronic cystitis and/or recurrent urinary tract infections (3 or more in the last year); * Any condition that, in the opinion of the Investigator, may render the research participant unfit to complete the study, including, but not limited to, cardiovascular disease (KILLIP \> 2, modified Forester \> IIa,35 recurrent ventricular arrhythmias) or non cardiovascular (eg, active malignancy other than basal cell carcinoma, cirrhosis, chronic lung disease, severe autoimmune disease); * Pregnancy or lactation; * Active participation in another clinical trial * Patients with septic shock or severe glycemic decompensation requiring the use of IV insulin at the time of randomization; * TGP/ALT(Alanine Amino Transferase) \>3x the upper limit of normality (ULN) or total bilirubin \>2.5 x ULN; * Estimated glomerular filtration rate (GFR) \< 45 ml/min/1.73m² , calculated by MDRD, or kidney transplant; * Known thrombophilias or thrombocytosis; * Blood dyscrasias or any disorder that causes hemolysis, previously known; * Hematological abnormality (Hb ≤ 11g/dL or \> 17g/dL, leukocytes ≤ 4500/mm³ or \>11000/mm³, platelet count \<150,000/mm³ or \> 450,000/mm³)